coteau ARQ.

LTGO

Latigo Biotherapeutics, Inc.
$15.02
−$1.55 (9.35%) Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-26%-9%+8%+25%+42%Aug 7Oct 23Sep 1452w high $25.9352w low $13.50
LTGOSPY
Wall St. Highest PT $73.00 (+386.0%) Wall St. Avg PT $52.25 (+247.9%)
$14$35$57$78$100POC $22Hi $73Avg $52
Underwater Drawdown %Max DD -44.0%Current -39.9%
0.0%-44.0%
Relative Strength vs SPY-16.2% vs SPYUnderperforming
+43%0%-43%
1W
+$1.02 (7.29%)
1M
−$4.95 (24.79%)
3M
–
6M
–
YTD
–
1Y
–

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
4 analysts · mean score 1.00
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$15.02
Average target$52.25
+$37.23 (+247.9%) upsideaverage target vs current price
CurrentAverageMedian
Low$36.00
Median$52.25
High$73.00
12-month Wall Street target range
Recent analyst rating changes · 3
Initiated
2026-09-01 · Leerink Partners started covering LTGO at Outperform
Initiated
2026-09-01 · Jefferies started covering LTGO at Buy
Initiated
2026-09-01 · Guggenheim started covering LTGO at Buy
All analyst rating changes ›

Third-party ratings, not Coteau's views.

Key stats & company

Market value$995.8M
P/E (next 12 months, estimated)-7.2
52-week range$13.50 – $25.93
Dividend yieldNo dividend
Analyst consensusStrong Buy (4)
Average analyst price target$52.25 (+248%)

What they do

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for LTGO yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 Coteau Physical AI Grid & Power
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

Earnings & events

LTGO earningsNext report in 18 days
Next report
Thu Nov 12, 2026Time not confirmed
EPS consensus-$0.59
Revenue consensus$0 4 analysts
Last 1 quarters · EPS vs estimate
Sep 3, 2026-$27.59est -$0.66−4048.9%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-24 02:50:59 ET
26-09-27.590.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-06-30$0–
2025-03-31$0–

News & catalysts

More news
The Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’
TipRanks · Sep 08
Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
GlobeNewswire · Sep 03
Latigo Biotherapeutics (LTGO) On IPO And Trial Data Looks About Right Valued
Simply Wall St. · Aug 09
Rating changes
Initiated
2026-09-01 · Leerink Partners started covering LTGO at Outperform
Initiated
2026-09-01 · Jefferies started covering LTGO at Buy
Initiated
2026-09-01 · Guggenheim started covering LTGO at Buy

Third-party analyst actions, not Coteau's views. All rating changes

Stats refreshed 2026-10-24 02:50:59 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, Coteau model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026